Mutational activation of RAS and GSP oncogenes in differentiated thyroid cancer and their biological implications

[1]  Melvin I. Simon,et al.  Diversity of G proteins in signal transduction , 1991, Science.

[2]  E. Kaplan,et al.  N-ras 61 oncogene mutations in Hürthle cell tumors. , 1990, Surgery.

[3]  Frank McCormick,et al.  The GTPase superfamily: a conserved switch for diverse cell functions , 1990, Nature.

[4]  S. Rubin,et al.  Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. , 1990, Molecular endocrinology.

[5]  M. Endo,et al.  Accumulation of p21ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activity. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Rodenhuis,et al.  K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. , 1990, The New England journal of medicine.

[7]  E. Kawasaki,et al.  Two G protein oncogenes in human endocrine tumors. , 1990, Science.

[8]  J. Fagin,et al.  Clonal composition of benign and malignant human thyroid tumors. , 1990, The Journal of clinical investigation.

[9]  Kaoru Kobayashi,et al.  Thyroid carcinoma in Graves' disease , 1990, World Journal of Surgery.

[10]  E. Bergstralh,et al.  Diagnostic and prognostic utility of flow cytometric DNA measurements in follicular thyroid tumors , 1990, World Journal of Surgery.

[11]  S. Filetti,et al.  Increased aggressiveness of thyroid cancer in patients with Graves' disease. , 1990, The Journal of clinical endocrinology and metabolism.

[12]  M. Fey,et al.  Assessment of clonality in human tumors: a review. , 1990, Cancer research.

[13]  G. Fleuren,et al.  Frequency and degree of aneuploidy in benign and malignant thyroid neoplasms , 1990, International journal of cancer.

[14]  H. Bourne,et al.  Mutations in the GTP-binding site of GS alpha alter stimulation of adenylyl cyclase. , 1989, The Journal of biological chemistry.

[15]  J. L. Bos,et al.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[16]  H Studer,et al.  Natural heterogeneity of thyroid cells: the basis for understanding thyroid function and nodular goiter growth. , 1989, Endocrine reviews.

[17]  N. Lemoine,et al.  High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. , 1989, Oncogene.

[18]  J. Dumont,et al.  Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro. , 1988, The Journal of clinical endocrinology and metabolism.

[19]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[20]  B. Caillou,et al.  Detection of activated ras oncogenes in human thyroid carcinomas. , 1988, Oncogene.

[21]  J. Hamming,et al.  Multivariate analysis of survival in differentiated thyroid cancer: the prognostic significance of the age factor. , 1988, European journal of cancer & clinical oncology.

[22]  C. Edmonds,et al.  HYPERTHYROIDISM AND THYROID CANCER , 1988, Clinical endocrinology.

[23]  E. Mazzaferri.  Papillary thyroid carcinoma: factors influencing prognosis and current therapy. , 1987, Seminars in oncology.

[24]  H. Röher,et al.  Thyrotropin (TSH) stimulates cell growth and DNA synthesis in monolayer cultures of human thyrocytes independent of the adenylate-cyclase system. , 1987, Acta endocrinologica. Supplementum.

[25]  H. Gerber,et al.  Age-related failure of endocytosis may be the pathogenetic mechanism responsible for "cold" follicle formation in the aging mouse thyroid. , 1987, Endocrinology.

[26]  G. Colletta,et al.  Induction of the c-fos oncogene by thyrotropic hormone in rat thyroid cells in culture. , 1986, Science.

[27]  B. Asselain,et al.  Multifactorial study of prognostic factors in differentiated thyroid carcinoma and a re‐evaluation of the importance of age , 1986, The British journal of surgery.

[28]  J. Ranstam,et al.  Is the EORTC prognostic index of thyroid cancer valid in differentiated thyroid carcinoma? Retrospective multivariate analysis of differentiated thyroid carcinoma with long follow‐up , 1986, Cancer.

[29]  J. Denef,et al.  Increased follicular heterogeneity in experimental colloid goiter produced by refeeding iodine excess after thyroid hyperplasia. , 1986, Endocrinology.

[30]  M. Viola,et al.  Expression of ras oncogene p21 in prostate cancer. , 1986, The New England journal of medicine.

[31]  O. Clark,et al.  Characterization of the thyrotropin receptor-adenylate cyclase system in neoplastic human thyroid tissue. , 1983, The Journal of clinical endocrinology and metabolism.

[32]  S. H. Wollman,et al.  Thyrotropin preparations are mitogenic for thyroid epithelial cells in follicles in suspension culture. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[33]  O. Clark.  TSH suppression in the management of thyroid nodules and thyroid cancer , 2005, World Journal of Surgery.

[34]  F. Hofstädter.  Frequency and morphology of malignant tumours of the thyroid before and after the introduction of iodine-prophylaxis , 2004, Virchows Archiv A.

[35]  A. Frilling,et al.  Growth regulation of normal thyroids and thyroid tumors in man. , 1990, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[36]  L. Birnbaumer,et al.  G proteins in signal transduction. , 1990, Annual review of pharmacology and toxicology.

[37]  H. Müller-Gärtner,et al.  Individually Different Proliferation Responses of Differentiated Thyroid Carcinomas to Thyrotropin , 1989 .

[38]  H. Bürgi,et al.  Iodine deficiency disorders in Europe. , 1989, Bulletin of the World Health Organization.

[39]  William E. Grizzle,et al.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis , 1987, Nature.

[40]  B. Vogelstein,et al.  Prevalence of ras gene mutations in human colorectal cancers , 1987, Nature.